Literature DB >> 22183507

Transplantation in 2011: New agents, new ideas and new hope.

Titte R Srinivas1, Bruce Kaplan.   

Abstract

The past year was marked by several excellent studies that represent important therapeutic advances in kidney transplantation or that further our understanding of the genetic basis of chronic allograft dysfunction, clinical tolerance and outcomes of kidney transplantation.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22183507     DOI： 10.1038/nrneph.2011.215

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  10 in total

1.  Influence of CIT-induced DGF on kidney transplant outcomes.

Authors:  L K Kayler; T R Srinivas; J D Schold
Journal:  Am J Transplant       Date:  2011-11-02       Impact factor: 8.086

2.  Population-based risk assessment of APOL1 on renal disease.

Authors:  David J Friedman; Julia Kozlitina; Giulio Genovese; Prachi Jog; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

3.  Identification of a B cell signature associated with renal transplant tolerance in humans.

Authors:  Kenneth A Newell; Adam Asare; Allan D Kirk; Trang D Gisler; Kasia Bourcier; Manikkam Suthanthiran; William J Burlingham; William H Marks; Ignacio Sanz; Robert I Lechler; Maria P Hernandez-Fuentes; Laurence A Turka; Vicki L Seyfert-Margolis
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

4.  Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

Authors:  Christian P Larsen; Thomas C Pearson; Andrew B Adams; Paul Tso; Nozomu Shirasugi; Elizabeth Strobert; Dan Anderson; Shannon Cowan; Karen Price; Joseph Naemura; John Emswiler; JoAnne Greene; Lori Ann Turk; Jurgen Bajorath; Robert Townsend; David Hagerty; Peter S Linsley; Robert J Peach
Journal:  Am J Transplant       Date:  2005-03       Impact factor: 8.086

5.  Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients.

Authors:  J J Lozano; A Pallier; M Martinez-Llordella; R Danger; M López; M Giral; M C Londoño; A Rimola; J P Soulillou; S Brouard; A Sánchez-Fueyo
Journal:  Am J Transplant       Date:  2011-08-09       Impact factor: 8.086

6.  The APOL1 gene and allograft survival after kidney transplantation.

Authors:  A M Reeves-Daniel; J A DePalma; A J Bleyer; M V Rocco; M Murea; P L Adams; C D Langefeld; D W Bowden; P J Hicks; R J Stratta; J-J Lin; D F Kiger; M D Gautreaux; J Divers; B I Freedman
Journal:  Am J Transplant       Date:  2011-04-12       Impact factor: 8.086

7.  Deceased-donor characteristics and the survival benefit of kidney transplantation.

Authors:  Robert M Merion; Valarie B Ashby; Robert A Wolfe; Dale A Distant; Tempie E Hulbert-Shearon; Robert A Metzger; Akinlolu O Ojo; Friedrich K Port
Journal:  JAMA       Date:  2005-12-07       Impact factor: 56.272

8.  Desensitization in HLA-incompatible kidney recipients and survival.

Authors:  Robert A Montgomery; Bonnie E Lonze; Karen E King; Edward S Kraus; Lauren M Kucirka; Jayme E Locke; Daniel S Warren; Christopher E Simpkins; Nabil N Dagher; Andrew L Singer; Andrea A Zachary; Dorry L Segev
Journal:  N Engl J Med       Date:  2011-07-28       Impact factor: 91.245

9.  Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.

Authors:  F Vincenti; C P Larsen; J Alberu; B Bresnahan; V D Garcia; J Kothari; P Lang; E Mancilla Urrea; P Massari; G Mondragon-Ramirez; R Reyes-Acevedo; K Rice; L Rostaing; S Steinberg; J Xing; M Agarwal; M B Harler; B Charpentier
Journal:  Am J Transplant       Date:  2011-10-12       Impact factor: 8.086

10.  A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Authors:  F Vincenti; B Charpentier; Y Vanrenterghem; L Rostaing; B Bresnahan; P Darji; P Massari; G A Mondragon-Ramirez; M Agarwal; G Di Russo; C-S Lin; P Garg; C P Larsen
Journal:  Am J Transplant       Date:  2010-03       Impact factor: 8.086
  10 in total
  4 in total

1.  Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients.

Authors:  T Akimova; B M Kamath; J W Goebel; K E C Meyers; E B Rand; A Hawkins; M H Levine; J C Bucuvalas; W W Hancock
Journal:  Am J Transplant       Date:  2012-09-20       Impact factor: 8.086

2.  IL-34 is a Treg-specific cytokine and mediates transplant tolerance.

Authors:  Séverine Bézie; Elodie Picarda; Jason Ossart; Laurent Tesson; Claire Usal; Karine Renaudin; Ignacio Anegon; Carole Guillonneau
Journal:  J Clin Invest       Date:  2015-09-21       Impact factor: 14.808

3.  MiR-146a regulates regulatory T cells to suppress heart transplant rejection in mice.

Authors:  Jian Lu; Weiwei Wang; Peiyuan Li; Xiaodong Wang; Chao Gao; Baotong Zhang; Xuezhi Du; Yanhong Liu; Yong Yang; Feng Qi
Journal:  Cell Death Discov       Date:  2021-06-17

4.  Malignancies in a renal transplant population: The St. Michael's Hospital experience.

Authors:  R Saleeb; H Faragalla; G M Yousef; R Stewart; C J Streutker
Journal:  Urol Ann       Date:  2016 Apr-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.